Every Form 4 that Carlsmed, Inc. (CARL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CARL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CARL filings page.
CARLSMED, INC. (CARL) reported that Casey M. Tansey, identified as a ten percent owner, purchased 200,000 shares of common stock on July 24, 2025 in an open-market or private transaction at $15.00 per share. Following this transaction, Tansey is reported as holding 200,000 shares, with the stock held by Casey M. Tansey as noted in the footnote. The amendment corrects an earlier Form 4 that omitted this purchase, and no Rule 10b5-1 trading plan is reported.
CARLSMED, INC. (CARL) reported that Chief Operating Officer Jeffrey Bertolini received a grant of stock options for 50,000 shares of common stock on September 8, 2026. The options have an exercise price of $15.23 per share, expire on September 7, 2036, and vest starting after a one-year cliff from September 8, 2026, then in equal quarterly installments while he remains in service. No Rule 10b5-1 trading plan is reported for this grant.
CARLSMED, INC. director Kevin C. O’Boyle received a grant of 13,698 shares of Common Stock as a stock award with no cash price per share. Following this grant, he directly holds 31,031 common shares. The award is structured as restricted stock units that each convert into one share upon vesting. These RSUs vest in full on the earlier of the day before Carlsmed’s 2027 annual meeting of stockholders or June 3, 2027, contingent on his continued service on the Board of Directors through that date.
Sidow Kevin reported acquisition or exercise transactions in this Form 4 filing.
CARLSMED, INC. director Kevin Sidow reported receiving an equity award in the form of 13,698 restricted stock units, each convertible into one share of Common Stock upon vesting. These RSUs vest in full on the earlier of the day before the company’s 2027 annual stockholder meeting or June 3, 2027, if he continues serving on the Board through that date. Following this grant, Sidow directly holds 73,264 shares of Common Stock, reflecting a routine, compensation-related increase in his equity stake.
ROOT JONATHAN D reported acquisition or exercise transactions in this Form 4 filing.
CARLSMED, INC. director Jonathan D. Root reported a compensation-related equity award and his updated shareholdings. He received a grant of 13,698 restricted stock units (RSUs), each convertible into one share of common stock upon vesting. These RSUs vest in full on the earlier of the day before the company’s 2027 annual stockholders meeting or June 3, 2027, if he continues serving on the Board through that date.
After this award, Root directly holds 497,697 shares of common stock. The filing also lists additional shares held indirectly through U.S. Venture Partners entities, where Root is a managing member and may be deemed to share voting and dispositive power but disclaims beneficial ownership except for any pecuniary interest.
CARLSMED, INC. director Philip M. Young received a grant of 13,698 restricted stock units (RSUs) of Common Stock on June 3, 2026. Each RSU converts into one share when it vests.
The RSUs vest in full on the earlier of the day before Carlsmed’s 2027 annual stockholder meeting or June 3, 2027, as long as Young continues serving on the board through that date. Following this award, he holds 31,031 shares directly, 53,333 shares indirectly through PMY Partners L.P., where he is sole general partner with voting and dispositive power, and additional shares through the Young Family Trust, where he is a trustee with similar authority.
Carlsmed, Inc. CEO and President Michael Cordonnier reported several stock option exercises and related share sales. On March 2 and 3, 2026, he exercised options for multiple blocks of common stock at exercise prices of $0.335 and $4.352 per share. He then sold 197,855 common shares at a weighted average price of $13.292 per share to cover the option exercise costs, withholding taxes, and associated broker fees under a broker-assisted cashless exercise.
Carlsmed, Inc. reported that Chief Commercial Officer William Scott Durall acquired 44,977 shares of common stock on January 28, 2026 at a price of $0 per share. These shares relate to restricted stock units, each representing the right to receive one share of common stock.
The RSUs will vest in three equal annual installments beginning on the first anniversary of the grant date, providing Durall with equity that vests over a multi-year period as long as the vesting conditions are met.
Carlsmed, Inc. director and Chief IP Officer Niall Casey received an equity award of 44,977 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Carlsmed common stock and will vest in three equal annual installments beginning on the first anniversary of the grant date of January 28, 2026.
Following this award, Casey beneficially owned 982,562 shares of Carlsmed common stock on a direct basis, according to the filing.
Carlsmed, Inc. CEO and President Michael Cordonnier, who also serves as a director, received an equity award of 117,316 shares of common stock on January 28, 2026. These are restricted stock units, each convertible into one share, vesting in three equal annual installments starting on the first anniversary of the grant date. Following this grant, he beneficially owned 1,356,646 shares of Carlsmed common stock in direct ownership.
Carlsmed, Inc. reported an equity award to its CFO and Treasurer, Leonard Greenstein. On 01/28/2026, he received 44,977 shares of common stock at a price of $0, tied to restricted stock units that each represent one future share if vesting conditions are met.
After this grant, Greenstein beneficially owned 188,346 shares directly. The RSUs vest in three equal annual installments beginning on the first anniversary of the grant date, so the award is spread over three years rather than delivered all at once.